Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-Adapted Adjuvant Chemoradiotherapy in Esophageal Adenocarcinoma
NCT02037048Phase 2Active, not recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Feb 2014
- Primary completion
- Mar 2022
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, Paclitaxel Micelles for Injection in esophageal adenocarcinoma (EAC), adenocarcinoma of the gastroesophageal junction, Gastric cardia adenocarcinoma (GCA), sponsored by Case Comprehensive Cancer Center. Started Feb 2014; status: active, not recruiting.
02
Drugs
carboplatinPaclitaxel Micelles for Injection
03
Conditions
esophageal adenocarcinoma (EAC)adenocarcinoma of the gastroesophageal junctionGastric cardia adenocarcinoma (GCA)
Beyond the preview
Go deeper on NCT02037048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037048.